AAT Double Nickase Plasmid (h): sc-401034-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- AAT Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- AAT Double Nickase Plasmid (h) and AAT Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SERPINA1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: AAT Antibody (H-7): sc-166018
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
AAT Double Nickase Plasmid (h) | sc-401034-NIC | 20 µg | $410.00 | |||
AAT Double Nickase Plasmid (h2) | sc-401034-NIC-2 | 20 µg | $410.00 |
SERPINA1 encodes alpha-1 antitrypsin (AAT), a secreted serine protease inhibitor that constrains neutrophil elastase and related proteases to preserve extracellular matrix integrity and limit protease-driven inflammatory signaling. AAT is synthesized primarily by hepatocytes and contributes to protease–antiprotease balance in the liver and lung, influencing tissue remodeling, oxidative stress responses, and cytokine-regulated acute-phase programs. Altered SERPINA1 function or expression is linked to proteostasis and secretion defects, aberrant extracellular proteolysis, and inflammation-associated tissue injury. These pathways make SERPINA1/AAT a useful node for studying serpin biology, protein folding/trafficking, and protease-regulated remodeling in human cell models.
AAT Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SERPINA1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SERPINA1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SERPINA1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SERPINA1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.